Current Price
Translational Development Acquisition Corp. Warrants (TDACW) provides institutional investors with a strategic entry point into the dynamic biotechnology and healthcare sectors through its SPAC framework. Positioned to i...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AACCOM INC | ACMM | — | — | — | — | — | — | — |
| 2. | AActions Se... | ACTS | — | — | — | — | — | — | — |
| 3. | AAegon Fund... | AEFC | — | — | — | — | — | — | — |
| 4. | AFederal Ag... | AGM-P-D | — | — | — | — | — | — | — |
| 5. | AArmada Hof... | AHH-P-A | — | — | — | — | — | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 19 | Mar 20 | Jun 20 | Sep 20 | Dec 20 | Mar 21 | Jun 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.25 |
COGS | 0 | 0 | 0 | 0 | 0 | 1.39 | 0.73 | 11.92 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | -1.39 | -0.73 | 20.33 |
Gross Profit % | - | - | - | - | - | - | - | 63.03% |
| 0 | 0 | 0.33 | 0.53 | 0.26 | 0.7 | 0.73 | 5.21 | |
EBIT | -0.32 | -0.26 | -0.33 | -0.53 | -0 | -0.7 | -0.73 | 15.12 |
OPM % | - | - | - | - | - | - | - | 46.89% |
Non-Operating Income | 0 | 0 | 0.08 | 0.01 | 0 | 0.85 | -2.06 | -3.97 |
PBT | 0.24 | -0 | -0.26 | -0.53 | -0 | 0.15 | -2.79 | 11.15 |
Income Tax | 0.05 | 0 | -0 | 0.16 | 0.22 | -0.05 | -0.08 | 0.07 |
Tax Rate % | 21.07% | -258.82% | 0.09% | -31.14% | -21155.8% | -33.13% | 2.84% | 0.65% |
Net Income | 0.19 | -0 | -0.26 | -0.69 | -0 | 0.2 | -2.71 | 11.15 |
NPM % | - | - | - | - | - | - | - | 34.58% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 |
|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0.7 | 0 | 1.39 |
Gross Profit | 0 | -0 | 0 | 0 | -1.39 |
Gross Profit % | - | - | - | - | - |
| 0 | 0 | 0.7 | 1.1 | 1.39 | |
EBIT | -0 | -0 | -0.7 | -1.1 | -1.39 |
OPM % | - | - | - | - | - |
Non-Operating Income | 0 | 0 | 2.48 | 4.32 | 0.36 |
PBT | -0 | -0 | 1.78 | 3.22 | -1.03 |
Income Tax | 0 | 0 | 0.37 | 0.69 | 0.22 |
Tax Rate % | - | - | 21.06% | 21.43% | -21.16% |
Net Income | -0 | -0 | 1.4 | 2.53 | -1.24 |
NPM % | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 |
|---|---|---|---|---|---|
| 0.06 | 0.14 | 1.26 | 0.06 | 0 | |
| 0 | 0 | 207.75 | 148.75 | 0.06 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.39 | 0 | 0.06 | -74.27 | -0.06 | |
| 0 | 0.4 | 0 | 0 | 0.06 | |
Total Assets | 0.45 | 0.55 | 209.07 | 74.54 | 0.06 |
| 0 | 0 | 0.01 | 0.01 | 0.05 | |
| 0.02 | 0.02 | 203.08 | 68.48 | 54.18 | |
| 0.42 | 0.53 | 0.85 | 0.36 | 16.87 | |
| 0 | 0 | 0.53 | 0.84 | -4.74 | |
| 0 | 0 | 202.69 | 68.34 | -12.11 | |
Total Liabilities | 0.45 | 0.55 | 407.16 | 138.02 | 54.24 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 |
|---|---|---|---|---|---|
| -0 | -0 | -0.6 | -1.53 | -1.85 | |
| 0 | 0 | -205.28 | 137.7 | 11.32 | |
| 0.06 | 0.09 | 206.99 | -137.38 | -8.55 | |
Net CFNet Cash Flow | 0.06 | 0.09 | 1.11 | -1.2 | 0.92 |
FCFFree Cash Flow | -0 | -0 | -0.6 | -1.53 | -1.85 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 |
|---|---|---|---|---|---|
| - | -1.7% | 1.4% | 1.9% | -2.0% | |
| 18.45 | 23.19 | 0.00 | 0.01 | 0.22 | |
| 0.13 | 0.27 | 1.38 | 0.16 | 0.19 | |
| - | 0.00 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | 1.00 | 1.00 | -0.43 | -0.60 | 1.49 |
Payout Ratio | - | - | - | - | - |
| - | - | - | - | - | |
| - | - | - | - | - | |
| - | - | - | - | - | |
| 2.00 | 4.00 | 4.00 | 3.00 | 1.00 | |
| - | - | - | - | - | |
| 0.00 | 0.00 | 33.33 | 33.33 | 50.00 | |
| - | - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Translational Development Acquisition Corp. Warrants, from SEC filings
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| % of shares outstanding | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 240.90% | 208.26% | 115.08% | 9.66% | 9.66% | 9.66% | 16.69% | 16.69% | 0.00 | |
ForeignForeign institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | <0.01% | 0.00 | |
Govt.Government & pensions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
Public | 0.00% | 0.00% | 0.00% | 90.34% | 90.34% | 90.34% | 83.31% | 83.31% | 0.00 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | +1 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Partnership | DE | 462,916 | 9.99% | SC 13G · 4 Nov 2026 | |
| Holding company | DE | 500,207 | 4.00% | SC 13G/A · 10 Aug 2026 | |
| Investment adviser | DE | 164,247 | 4.00% | SC 13G/A · 14 Nov 2025 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | % of shares out | Days to cover | Relative size |
|---|---|---|---|---|---|
| 30 Oct 2026 | 53 | -48.0% | <0.01% | 1.00 | |
| 15 Oct 2026 | 102 | -62.5% | <0.01% | 1.00 | |
| 30 Sep 2026 | 272 | +123.0% | <0.01% | 1.00 | |
| 15 Sep 2026 | 122 | -6.2% | <0.01% | 1.00 | |
| 31 Aug 2026 | 130 | +116.7% | <0.01% | 1.00 | |
| 14 Aug 2026 | 60 | 0.0% | <0.01% | 1.00 | |
| 31 Jul 2026 | 60 | -94.6% | <0.01% | 1.00 | |
| 15 Jul 2026 | 1,107 | +69.3% | <0.01% | 1.00 | |
| 30 Jun 2026 | 654 | +53.2% | <0.01% | 1.00 | |
| 15 Jun 2026 | 427 | -93.3% | <0.01% | 1.00 | |
| 29 May 2026 | 6,336 | 0.03% | 1.00 | ||
| 27 Feb 2026 | 1 | <0.01% | 1.00 | ||
| 30 Jan 2026 | 49 | -9.3% | <0.01% | 1.00 | |
| 15 Jan 2026 | 54 | +10.2% | <0.01% | 1.00 | |
| 31 Dec 2025 | 49 | 0.0% | <0.01% | 2.58 | |
| 15 Dec 2025 | 49 | +16.7% | <0.01% | 1.00 | |
| 28 Nov 2025 | 42 | -94.0% | <0.01% | 1.00 | |
| 14 Nov 2025 | 704 | +2.3% | <0.01% | 1.00 | |
| 31 Oct 2025 | 688 | -93.2% | <0.01% | 1.00 | |
| 15 Oct 2025 | 10,081 | -1.9% | 0.04% | 25.33 | |
| 30 Sep 2025 | 10,281 | -48.4% | 0.05% | 1.00 | |
| 15 Sep 2025 | 19,922 | -9.6% | 0.09% | 4.47 | |
| 29 Aug 2025 | 22,032 | +304.9% | 0.10% | 2.84 | |
| 15 Aug 2025 | 5,441 | -6.2% | 0.02% | 1.82 |
FINRA consolidated short interest, reported twice a month for every US listing.
Translational Development Acquisition Corp. Warrants's SEC filings and earnings call transcripts
What recent news says about Translational Development Acquisition Corp. Warrants, scored for sentiment.